
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5730937/publications.pdf Version: 2024-02-01



Δυλ Κωονις

#	Article	IF	CITATIONS
1	Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 382.</emph 	3.8	546
2	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
3	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
4	Circulating microRNAs as Specific Biomarkers for Breast Cancer Detection. PLoS ONE, 2013, 8, e53141.	1.1	212
5	Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. Cell Death and Disease, 2019, 10, 270.	2.7	174
6	MRI background enhancement: Its relationship with breast density and breast cancer risk. Journal of Clinical Oncology, 2007, 25, 1539-1539.	0.8	145
7	Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. British Journal of Cancer, 2015, 112, 1751-1759.	2.9	127
8	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
9	Mammographic density and ageing: A collaborative pooled analysis of cross-sectional data from 22 countries worldwide. PLoS Medicine, 2017, 14, e1002335.	3.9	108
10	International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. British Journal of Cancer, 2019, 121, 15-21.	2.9	101
11	Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis. PLoS ONE, 2012, 7, e43994.	1.1	93
12	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
13	First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Annals of Oncology, 2011, 22, 595-602.	0.6	92
14	A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer. Molecular Cancer, 2015, 14, 202.	7.9	92
15	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
16	Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. Journal of the National Cancer Institute, 2019, 111, 1298-1306.	3.0	83
17	Comprehensive spectrum of <i>BRCA1</i> and <i>BRCA2</i> deleterious mutations in breast cancer in Asian countries. Journal of Medical Genetics, 2016, 53, 15-23.	1.5	82
18	miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer. BMC Cancer, 2016, 16, 887.	1.1	81

#	Article	IF	CITATIONS
19	MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells. Tumor Biology, 2014, 35, 2591-2598.	0.8	79
20	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33.	2.2	78
21	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
22	Interpreting differences in patterns of supportive care needs between patients with breast cancer and patients with colorectal cancer. Psycho-Oncology, 2013, 22, 792-798.	1.0	72
23	Supportive care needs in Hong Kong Chinese women confronting advanced breast cancer. Psycho-Oncology, 2013, 22, 1144-1151.	1.0	72
24	Validation of the Chinese version of the Shortâ€form Supportive Care Needs Survey Questionnaire (SCNS‣F34). Psycho-Oncology, 2011, 20, 1292-1300.	1.0	68
25	ldiopathic granulomatous mastitis: a 10-year study from a multicentre clinical database. Pathology, 2018, 50, 742-747.	0.3	66
26	Acetylcholine receptors: Key players in cancer development. Surgical Oncology, 2019, 31, 46-53.	0.8	58
27	Breast Cancer in Chinese Women Younger than Age 40: Are They Different from Their Older Counterparts?. World Journal of Surgery, 2008, 32, 2554-61.	0.8	55
28	Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast and Gastric Cancer Patients. PLoS ONE, 2011, 6, e22233.	1.1	53
29	Does the use of shared decision-making consultation behaviors increase treatment decision-making satisfaction among Chinese women facing decision for breast cancer surgery?. Patient Education and Counseling, 2014, 94, 243-249.	1.0	52
30	Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer. Oncologist, 2011, 16, 1535-1546.	1.9	50
31	Common Variants at the 19p13.1 and <i>ZNF365</i> Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	1.1	47
32	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. American Journal of Human Genetics, 2018, 103, 3-18.	2.6	46
33	Breast Cancer in Hong Kong, Southern China: The First Population-Based Analysis of Epidemiological Characteristics, Stage-Specific, Cancer-Specific, and Disease-Free Survival in Breast Cancer Patients: 1997–2001. Annals of Surgical Oncology, 2011, 18, 3072-3078.	0.7	44
34	Psychometric assessment of the <scp>C</scp> hinese version of the decisional conflict scale in <scp>C</scp> hinese women making decision for breast cancer surgery. Health Expectations, 2015, 18, 210-220.	1.1	43
35	The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer. Cancer Genetics, 2015, 208, 448-454.	0.2	43
36	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	2.2	42

#	Article	IF	CITATIONS
37	Breast-conserving surgery <i>versus</i> mastectomy in young women with breast cancer in Asian settings. BJS Open, 2019, 3, 48-55.	0.7	42
38	A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Research and Treatment, 2009, 117, 683-686.	1.1	40
39	Detection of Methylated Circulating DNA as Noninvasive Biomarkers for Breast Cancer Diagnosis. Journal of Breast Cancer, 2017, 20, 12.	0.8	40
40	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	2.6	39
41	Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel. Journal of Molecular Diagnostics, 2016, 18, 580-594.	1.2	38
42	Factors that Can Promote or Impede the Advancement of Women as Leaders in Surgery: Results from an International Survey. World Journal of Surgery, 2016, 40, 258-266.	0.8	38
43	Plasma miR-940 may serve as a novel biomarker for gastric cancer. Tumor Biology, 2016, 37, 3589-3597.	0.8	37
44	The genetic interplay between body mass index, breast size and breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 781-794.	0.9	37
45	Mammographic Screening in Women at Increased Risk of Breast Cancer after Treatment of Hodgkin's Disease. Breast Journal, 2008, 14, 39-48.	0.4	35
46	Ovarian cancer susceptibility alleles and risk of ovarian cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
47	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
48	Mammary phyllodes tumour: a 15-year multicentre clinical review. Journal of Clinical Pathology, 2018, 71, 493-497.	1.0	31
49	Fear of cancer recurrence among Chinese cancer survivors: Prevalence and associations with metacognition and neuroticism. Psycho-Oncology, 2019, 28, 1243-1251.	1.0	31
50	Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer. The HUGO Journal, 2009, 3, 63-76.	4.1	30
51	MicroRNAs as New Players for Diagnosis, Prognosis, and Therapeutic Targets in Breast Cancer. Journal of Oncology, 2009, 2009, 1-6.	0.6	29
52	Prognostic role of adjuvant radiotherapy in tripleâ€negative breast cancer: A historical cohort study. International Journal of Cancer, 2015, 137, 2504-2512.	2.3	28
53	The acceptance and feasibility of breast cancer screening in the East. Breast, 2008, 17, 42-50.	0.9	27
54	Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. Familial Cancer. 2012. 11. 429-439.	0.9	27

Ανα Κωοης

#	Article	IF	CITATIONS
55	Evaluation of patient effective dose from sentinel lymph node lymphoscintigraphy in breast cancer: A phantom study with SPECT/CT and ICRP-103 recommendations. European Journal of Radiology, 2012, 81, e717-e720.	1.2	27
56	Comparing the meanings of living with advanced breast cancer between women resilient to distress and women with persistent distress: a qualitative study. Psycho-Oncology, 2017, 26, 255-261.	1.0	27
57	BAMClipper: removing primers from alignments to minimize false-negative mutations in amplicon next-generation sequencing. Scientific Reports, 2017, 7, 1567.	1.6	27
58	Polygenic risk scores for prediction of breast cancer risk in Asian populations. Genetics in Medicine, 2022, 24, 586-600.	1.1	27
59	Choice of Management of Southern Chinese BRCA Mutation Carriers. World Journal of Surgery, 2010, 34, 1416-1426.	0.8	26
60	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2016, 157, 319-327.	1.1	26
61	BRCA2 lossâ€ofâ€function germline mutations are associated with esophageal squamous cell carcinoma risk in Chinese. International Journal of Cancer, 2020, 146, 1042-1051.	2.3	26
62	Waiting to see the doctor: understanding appraisal and utilization components of consultation delay for new breast symptoms in Chinese women. Psycho-Oncology, 2012, 21, 1316-1323.	1.0	25
63	The Attitude and Perceptions of Work–life Balance: A Comparison Among Women Surgeons in Japan, USA, and Hong Kong China. World Journal of Surgery, 2013, 37, 2-11.	0.8	25
64	Delayed presentation, diagnosis, and psychosocial aspects of male breast cancer. Cancer Medicine, 2020, 9, 3305-3309.	1.3	25
65	Male Breast Cancer: A Population-Based Comparison with Female Breast Cancer in Hong Kong, Southern China: 1997–2006. Annals of Surgical Oncology, 2014, 21, 1246-1253.	0.7	24
66	Goal adjustment influence on psychological wellâ€being following advanced breast cancer diagnosis. Psycho-Oncology, 2016, 25, 58-65.	1.0	24
67	MiR-92 suppresses proliferation and induces apoptosis by targeting EP4/Notch1 axis in gastric cancer. Oncotarget, 2018, 9, 24209-24220.	0.8	24
68	BRCA1 deficiency induces protective autophagy to mitigate stress and provides a mechanism for BRCA1 haploinsufficiency in tumorigenesis. Cancer Letters, 2014, 346, 139-147.	3.2	23
69	Germline RECQL mutations in high risk Chinese breast cancer patients. Breast Cancer Research and Treatment, 2016, 157, 211-215.	1.1	23
70	Predicting Outcome in Mammary Phyllodes Tumors: Relevance of Clinicopathological Features. Annals of Surgical Oncology, 2019, 26, 2747-2758.	0.7	23
71	What Made Her Give Up Her Breasts: a Qualitative Study on Decisional Considerations for Contralateral Prophylactic Mastectomy among Breast Cancer Survivors Undergoing BRCA1/2 Genetic Testing. Asian Pacific Journal of Cancer Prevention, 2012, 13, 2241-2247.	0.5	23
72	Development and pilot-testing of a Decision Aid for use among Chinese women facing breast cancer surgery. Health Expectations, 2011, 14, 405-416.	1.1	22

#	Article	IF	CITATIONS
73	Breast Conserving Surgery for BRCA Mutation Carriers—A Systematic Review. Clinical Breast Cancer, 2020, 20, e244-e250.	1.1	22
74	Resveratrol enhanced chemosensitivity by reversing macrophage polarization in breast cancer. Clinical and Translational Oncology, 2022, 24, 854-863.	1.2	22
75	A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer. Familial Cancer, 2011, 10, 233-237.	0.9	21
76	Factors affecting the under-diagnosis of atypical ductal hyperplasia diagnosed by core needle biopsies – A 10-year retrospective study and review of the literature. International Journal of Surgery, 2018, 49, 27-31.	1.1	21
77	Methylated Septin 9 and Carcinoembryonic Antigen for Serological Diagnosis and Monitoring of Patients with Colorectal Cancer After Surgery. Scientific Reports, 2019, 9, 10326.	1.6	21
78	Sentinel lymph node technique for breast cancer: radiation safety issues. Seminars in Oncology, 2004, 31, 298-303.	0.8	20
79	Efficacy of surgical masks or cloth masks in the prevention of viral transmission: Systematic review, metaâ€analysis, and proposal for future trial. Journal of Evidence-Based Medicine, 2021, 14, 97-111.	0.7	20
80	Accuracy of BRCA1/2ÂMutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort. World Journal of Surgery, 2012, 36, 702-713.	0.8	19
81	Diabetic Mastopathy. Breast Journal, 2013, 19, n/a-n/a.	0.4	19
82	International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiology, 2016, 40, 141-151.	0.8	19
83	INDELseek: detection of complex insertions and deletions from next-generation sequencing data. BMC Genomics, 2017, 18, 16.	1.2	19
84	Factors predicting patient satisfaction in women with advanced breast cancer: a prospective study. BMC Cancer, 2018, 18, 162.	1.1	19
85	The role of metacognition and its indirect effect through cognitive attentional syndrome on fear of cancer recurrence trajectories: A longitudinal study. Psycho-Oncology, 2020, 29, 271-279.	1.0	19
86	Complications in Post-mastectomy Immediate Breast Reconstruction: A Ten-year Analysis of Outcomes. Clinical Breast Cancer, 2020, 20, 402-407.	1.1	19
87	Management of granulomatous lobular mastitis: an international multidisciplinary consensus (2021) Tj ETQq1	1 0.784314 1.9	4 rg <u>B</u> T /Overld
88	Breast onserving Surgery in Hong Kong Chinese Women. World Journal of Surgery, 2008, 32, 2549-53.	0.8	18
89	Association of clinicopathological features and prognosis of TERT alterations in phyllodes tumor of breast. Scientific Reports, 2018, 8, 3881.	1.6	18
90	Cutaneous Angiosarcoma Secondary to Lymphoedema or Radiation Therapy — A Systematic Review. Clinical Oncology, 2019, 31, 225-231.	0.6	18

Ανα Κωοης

#	Article	IF	CITATIONS
91	Global Disparities in Breast Cancer Genetics Testing, Counselling and Management. World Journal of Surgery, 2019, 43, 1264-1270.	0.8	18
92	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 106-115.	3.2	18
93	Mammographic density assessed on paired raw and processed digital images and on paired screen-film and digital images across three mammography systems. Breast Cancer Research, 2016, 18, 130.	2.2	17
94	Sentinel Lymph Node Biopsy in Early Breast Cancer: Magnetic Tracer as the Only Localizing Agent. World Journal of Surgery, 2019, 43, 1991-1996.	0.8	17
95	Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients. Journal of Molecular Diagnostics, 2020, 22, 544-554.	1.2	17
96	Electroacupuncture trigeminal nerve stimulation plus body acupuncture for chemotherapy-induced cognitive impairment in breast cancer patients: An assessor-participant blinded, randomized controlled trial. Brain, Behavior, and Immunity, 2020, 88, 88-96.	2.0	17
97	Coexistence of Ductal Carcinoma Within Mammary Phyllodes Tumor: A Review of 557 Cases From a 20-year Region-wide Database in Hong Kong and Southern China. Clinical Breast Cancer, 2018, 18, e421-e425.	1.1	16
98	Circulating high-sensitivity troponin T and microRNAs as markers of myocardial damage during childhood leukaemia treatment. Pediatric Research, 2021, 89, 1245-1252.	1.1	16
99	Triple Negative Status is a Poor Prognostic Indicator in Chinese Women with Breast Cancer: a Ten Year Review. Asian Pacific Journal of Cancer Prevention, 2012, 13, 2109-2114.	0.5	16
100	targeting as a therapeutic approach for treatment of metastatic breast cancer. American Journal of Cancer Research, 2020, 10, 211-223.	1.4	16
101	Telephone pre-anaesthesia assessment for ambulatory breast surgery. Hong Kong Medical Journal, 2009, 15, 179-82.	0.1	16
102	Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family. Familial Cancer, 2008, 7, 125-133.	0.9	15
103	COVID-19 vaccine associated axillary lymphadenopathy – A systematic review. Cancer Treatment and Research Communications, 2022, 31, 100546.	0.7	15
104	Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients. Breast Cancer Research and Treatment, 2012, 136, 931-933.	1.1	14
105	Identifying risk factors for brain metastasis in breast cancer patients: Implication for a vigorous surveillance program. Asian Journal of Surgery, 2015, 38, 220-223.	0.2	14
106	Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. EBioMedicine, 2019, 48, 203-211.	2.7	14
107	Functional Implications of Cathelicidin Antimicrobial Protein in Breast Cancer and Tumor-Associated Macrophage Microenvironment. Biomolecules, 2020, 10, 688.	1.8	13
108	Nipple-Sparing Mastectomy and Its Application on BRCA Gene Mutation Carrier. Clinical Breast Cancer, 2017, 17, 581-584.	1.1	12

#	Article	IF	CITATIONS
109	Forward and reverse mutations in stages of cancer development. Human Genomics, 2018, 12, 40.	1.4	12
110	Copy number variation analysis based on AluScan sequences. Journal of Clinical Bioinformatics, 2014, 4, 15.	1.2	11
111	The role of cognitive bias in relation to persistent distress among women diagnosed with breast cancer. Psycho-Oncology, 2018, 27, 983-989.	1.0	11
112	Ductal carcinoma in situ of the breast - Long term results from a twenty-year cohort. Cancer Treatment and Research Communications, 2018, 14, 17-20.	0.7	11
113	Survival analysis of breast cancer liver metastasis treated by hepatectomy: A propensity score analysis for Chinese women in Hong Kong. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 452-457.	0.6	11
114	De-novo metastatic breast cancers with or without primary tumor resection – A 10-year study. Cancer Treatment and Research Communications, 2019, 19, 100118.	0.7	11
115	A new paradigm of genetic testing for hereditary breast/ovarian cancers. Hong Kong Medical Journal, 2016, 22, 171-7.	0.1	11
116	Work–life balance of female versus male surgeons in Hong Kong based on findings of a questionnaire designed by a Japanese surgeon. Surgery Today, 2014, 44, 62-72.	0.7	10
117	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	1.1	10
118	Circulating Micro <scp>RNA</scp> in patients with repaired tetralogy of Fallot. European Journal of Clinical Investigation, 2017, 47, 574-582.	1.7	10
119	Air Travel and Postoperative Lymphedema—A Systematic Review. Clinical Breast Cancer, 2018, 18, e151-e155.	1.1	10
120	Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients. BMC Cancer, 2020, 20, 1053.	1.1	10
121	Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review. Breast Cancer Research and Treatment, 2021, 186, 607-615.	1.1	10
122	Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis. American Journal of Cancer Research, 2015, 5, 3389-99.	1.4	10
123	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. Genetics in Medicine, 2022, 24, 119-129.	1.1	10
124	Chrysomya bezziana: A Rare Infestation of the Breast. Breast Journal, 2007, 13, 297-301.	0.4	9
125	Micro <scp>RNA</scp> s are differentially deregulated in mammary malignant phyllodes tumour. Histopathology, 2015, 67, 294-305.	1.6	9
126	database.bio: a web application for interpreting human variations. Bioinformatics, 2015, 31, 4035-4037.	1.8	9

#	Article	IF	CITATIONS
127	Rapid detection of <i>BRCA1/2</i> recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. Oncotarget, 2018, 9, 7832-7843.	0.8	9
128	Is sentinel lymph node biopsy after neoadjuvant chemotherapy feasible in Chinese patients with invasive breast cancers?. ANZ Journal of Surgery, 2009, 79, 719-723.	0.3	8
129	Surgical Margins in Breast Conservation Therapy: How Much Should We Excise?. Southern Medical Journal, 2009, 102, 1234-1237.	0.3	8
130	Elevation of methylated DNA in KILLIN/PTEN in the plasma of patients with thyroid and/or breast cancer. OncoTargets and Therapy, 2014, 7, 2085.	1.0	8
131	Breast and ovarian cancer penetrance of <i>BRCA1/2</i> mutations among Hong Kong women. Oncotarget, 2018, 9, 25025-25033.	0.8	8
132	Germline PALB2 Mutation in High-Risk Chinese Breast and/or Ovarian Cancer Patients. Cancers, 2021, 13, 4195.	1.7	7
133	Localization of hRad9 in breast cancer. BMC Cancer, 2008, 8, 196.	1.1	6
134	Conversion rate from mastectomy to breast conservation after neoadjuvant dual target therapy for HER2-positive breast cancer in the Asian population. Breast Cancer, 2020, 27, 456-463.	1.3	6
135	Could ductoscopy alleviate the need of microdochectomy in pathological nipple discharge?. Breast Cancer, 2020, 27, 607-612.	1.3	6
136	Long-term Survival Outcomes of â€~Low Risk' Ductal Carcinoma in situ from a Territory-wide Cancer Registry. Clinical Oncology, 2021, 33, 40-45.	0.6	6
137	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	2.6	6
138	Genetic testing for hereditary breast cancer in Asia—moving forward. Chinese Clinical Oncology, 2016, 5, 47-47.	0.4	6
139	High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients. Breast Cancer Research and Treatment, 2010, 122, 605-607.	1.1	5
140	Air Travel Safety in Postoperative Breast Cancer Patients: A Systematic Review. Clinical Breast Cancer, 2018, 18, e813-e817.	1.1	5
141	A Case Report of Germline Compound Heterozygous Mutations in the BRCA1 Gene of an Ovarian and Breast Cancer Patient. International Journal of Molecular Sciences, 2021, 22, 889.	1.8	5
142	Somatic mutation profiling in -negative breast and ovarian cancer patients by multigene panel sequencing. American Journal of Cancer Research, 2020, 10, 2919-2932.	1.4	5
143	Germline mutations in Chinese ovarian cancer with or without breast cancer. Molecular Genetics & Genomic Medicine, 2022, 10, .	0.6	5
144	Mastectomy technique using a self-designed self-retaining retractor system. Surgery Today, 2017, 47, 265-269.	0.7	4

#	Article	IF	CITATIONS
145	Young onset breast cancer in Southern China – a 5-year clinico-pathological study from a multi-centre database. Cancer Treatment and Research Communications, 2020, 24, 100182.	0.7	4
146	Non-surgical treatment for ductal carcinoma in situ of the breasts – a prospective study on patient's perspective. Cancer Treatment and Research Communications, 2021, 26, 100241.	0.7	4
147	Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study. Breast Cancer Research and Treatment, 2021, 187, 759-768.	1.1	4
148	Human haptoglobin contributes to breast cancer oncogenesis through glycolytic activity modulation. American Journal of Cancer Research, 2020, 10, 2865-2877.	1.4	4
149	Attitudes and compliance of clinical management after genetic testing for hereditary breast and ovarian cancer among high-risk Southern Chinese females with breast cancer history. Familial Cancer, 2014, 13, 423-430.	0.9	3
150	Response to: Comment on â€~Circulating cell-free miRNAs as biomarker for triple-negative breast cancer'. British Journal of Cancer, 2016, 114, e6-e6.	2.9	3
151	Preoperative Sentinel Node Mapping in Sentinel Node Biopsy in Early Breast Cancers – Is It Cost-Effective?. Clinical Breast Cancer, 2017, 17, 134-138.	1.1	3
152	Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy. Postgraduate Medical Journal, 2019, 95, 155-161.	0.9	3
153	Matched case-control survival analysis of older chinese breast cancer patients treated with surgery or primary endocrine therapy. Cancer Treatment and Research Communications, 2020, 25, 100227.	0.7	3
154	Prospective clinical trial on highâ€intensity focused ultrasound for the treatment of breast fibroadenoma. Breast Journal, 2021, 27, 294-296.	0.4	3
155	Baseline knowledge and receptiveness to genetic testing for hereditary breast and ovarian cancer syndromes in Chinese high-risk females. Journal of Community Genetics, 2021, 12, 431-438.	0.5	3
156	Dietary decision-making in Chinese breast cancer survivors: A qualitative study. Patient Education and Counseling, 2022, 105, 460-465.	1.0	3
157	FACTORS AFFECTING FALSE-NEGATIVE BREAST SENTINEL NODE BIOPSY IN CHINESE PATIENTS. ANZ Journal of Surgery, 2007, 77, 866-869.	0.3	2
158	BRCAmutation testing for ovarian cancer in the context of available targeted therapy: Survey and consensus of Hong Kong specialists. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 20-31.	0.7	2
159	Breast Implant-associated Anaplastic Large Cell Lymphoma – a Systematic Review with Pooled Analysis. Clinical Oncology, 2020, 32, 639-646.	0.6	2
160	Breast Cancer Rate and Mortality in Female Flight Attendants: A Systematic Review and Pooled Analysis. Clinical Breast Cancer, 2020, 20, 371-376.	1.1	2
161	Prospective clinical trial on the learning curve of high-intensity-focused ultrasound for the treatment of breast fibroadenoma. Surgery Today, 2022, , 1.	0.7	2
162	Experience of Southern Chinese: new challenges in treating young female breast cancer patients at child-bearing agea call for multi-disciplinary collaboration. Asian Pacific Journal of Cancer Prevention, 2012, 13, 3535-7.	0.5	2

#	Article	IF	CITATIONS
163	Long term survival study of de-novo metastatic breast cancers with or without primary tumour resection. Cancer Treatment and Research Communications, 2019, 20, 100148.	0.7	1
164	Co-existing malignant lesions in atypical ductal hyperplasia – Pathology, probability, predictors and prognosis. Asian Journal of Surgery, 2020, 43, 240-243.	0.2	1
165	The practice of breast reconstruction with abdominal tissue in a Hong Kong high caseload centre. Surgical Practice, 2020, 24, 48-54.	0.1	1
166	Rapid Breakpoint Mapping of a Novel Germline <i>PALB2</i> Duplication by PCR-Free Long-Read Sequencing for Interpretation of Its Pathogenicity. JCO Precision Oncology, 2021, 5, 1044-1047.	1.5	1
167	Decision aids for breast cancer surgery: a randomised controlled trial. Hong Kong Medical Journal, 2014, 20 Suppl 7, 24-7.	0.1	1
168	Screening for founder and recurrent BRCA mutations in Hong Kong and US Chinese populations. Hong Kong Medical Journal, 2018, 24 Suppl 3, 4-6.	0.1	1
169	Relevance of the MHC region for breast cancer susceptibility in Asians. Breast Cancer, 2022, 29, 869-879.	1.3	1
170	P134 The experience of sentinel lymph node biopsy in Chinese breast cancer patients with prior neo-adjuvant chemotherapy. Breast, 2007, 16, S51.	0.9	0
171	Breastâ€Conserving Surgery in Asian Women: Benefits and Potential Harms: Reply to Letter. World Journal of Surgery, 2009, 33, 1550-1551.	0.8	0
172	396 Role of miR-143 regulating DNA methyltransferases 3A in breast cancer. European Journal of Cancer, Supplement, 2010, 8, 172-173.	2.2	0
173	Managing <i>BRCA</i> Mutation Carriers in China: Reply . World Journal of Surgery, 2011, 35, 460-461.	0.8	0
174	Do elderly breast cancer patients have poorer survival outcome? "CSC2017 abstract― Surgical Practice, 2018, 23, 14.	0.1	0
175	Using Risk Stratification to Optimize Mammography Screening in Chinese Women. JNCI Cancer Spectrum, 2021, 5, pkab060.	1.4	0
176	Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers. Advances in Therapy, 2021, 38, 5752-5762.	1.3	0
177	Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family. Journal of Clinical Oncology, 2007, 25, 10541-10541.	0.8	0
178	Novel de novo BRCA1 mutation in a woman with early onset breast cancer. Journal of Clinical Oncology, 2009, 27, e22143-e22143.	0.8	0
179	Abstract 3027: Plasma microRNA as a potential marker for breast cancer detection. , 2010, , .		0
180	Abstract P4-11-02: NovelBRCA1andBRCA2genomic rearrangements in Southern Chinese breast/ovarian cancer patients. , 2012, , .		0

Ανα Κωονς

#	Article	IF	CITATIONS
181	The genetics of breast cancer, risk-reducing surgery and prevention. , 2014, , 127-145.		0
182	Body mass index and type 2 diabetes and breast cancer survival: a Mendelian randomization study. American Journal of Cancer Research, 2021, 11, 3921-3934.	1.4	0
183	Clinical outcomes of patients with ductal carcinoma in situ in Hong Kong: 10-year territory-wide cancer registry study. , 2020, 26, 486-491.		0
184	MicroRNA-199a-3p promotes drug sensitivity in triple negative breast cancer by down-regulation of American Journal of Translational Research (discontinued), 2022, 14, 2021-2036.	0.0	0
185	Genetic counselling and testing for breast and ovarian cancer in Asia: A multinational survey of unmet needs Journal of Clinical Oncology, 2022, 40, 10586-10586.	0.8	0